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Abstract
The aim of the present study was to examine constitutive signal transducer and activator of
transcription 3 (STAT3) phosphorylation in circulating leukocytes as a candidate biomarker
in rheumatoid arthritis (RA). 25 patients with recent-onset, untreated RA provided samples
for whole blood flow cytometric determination of intracellular STAT3 phosphorylation,
expressed as relative fluorescence units. The occurrence of constitutive STAT3 phosphory-
lation was evaluated by determining proportion of STAT3-phosphorylated cells among dif-
ferent leukocyte subtypes. Plasma levels of interleukin (IL)-6, IL-17 and IL-21 were
measured by immunoassay, radiographs of hands and feet were examined and disease
activity score (DAS28) was determined. Biomarkers were restudied and treatment response
(according to European League Against Rheumatism) was determined after 12 months of
treatment with disease-modifying antirheumatic drugs. At baseline, constitutive phosphory-
lation of STAT3 occurred in CD4+ T cells of 14 (56%) patients, CD8+ T cells of 13 (52%)
patients, in CD19+ B cells of 7 (28%) patients, and in CD14+ monocytes of 12 (48%)
patients. STAT3 phosphorylation levels of CD4+ T cells associated with DAS28, and those
of all leukocyte subtypes studied associated with erosive disease. The presence of constitu-
tive STAT3 phosphorylation in CD4+ T lymphocytes, pSTAT3 fluorescence intensity of
CD4+ and CD8+ T cells and C-reactive protein (CRP) levels at baseline associated with
good treatment response. In conclusion, constitutive STAT3 phosphorylation in circulating
CD4+ T cells is common in recent-onset untreated RA and associates with good treatment
response in patients characterized by high disease activity and the presence of systemic
inflammation.
PLOS ONE | DOI:10.1371/journal.pone.0137385 September 9, 2015 1 / 15
OPEN ACCESS
Citation: Kuuliala K, Kuuliala A, Koivuniemi R,
Oksanen S, Hämäläinen M, Moilanen E, et al. (2015)
Constitutive STAT3 Phosphorylation in Circulating
CD4+ T Lymphocytes Associates with Disease
Activity and Treatment Response in Recent-Onset
Rheumatoid Arthritis. PLoS ONE 10(9): e0137385.
doi:10.1371/journal.pone.0137385
Editor: Oreste Gualillo, SERGAS (Servizo Galego de
Saude) and IDIS (Instituto de Investigación Sanitaria
de Santiago), the NEIRID Lab, Research Laboratory
9, Santiago University Clinical Hospital. Santiago de
Compostela, SPAIN
Received: March 31, 2015
Accepted: August 16, 2015
Published: September 9, 2015
Copyright: © 2015 Kuuliala et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by Paulo
Foundation and Finnish Cultural Foundation (to KK);
Helsinki University Central Hospital Research Funds
(to MLR and HR); and Finska Läkaresällskapet (to
MLR and HR). The funders had no role in study
Introduction
Rheumatoid arthritis (RA) is a chronic, heterogeneous inflammatory disease with autoimmune
origin. The treatment options include disease-modifying antirheumatic drugs (DMARDs), bio-
logical DMARDs targeted against the actions of T cells, B cells, the inflammatory cytokines
tumour necrosis factor (TNF) or interleukin (IL)-6, and small molecular inhibitors of intracel-
lular kinases [1,2]. At present, there are virtually no tests that could reliably predict the individ-
ual disease course and response to the chosen treatment. Hence, it would be of great value to
find novel biomarkers that help support the diagnosis, reveal the contribution of different
immune cell types and activity of inflammatory processes, and predict the progression of the
disease and the efficacy and suitability of the treatment strategies.
Conventionally, plasma/serum samples have been used in order to find helpful biomarkers
for RA activity and progression [3–7]. However, levels of these marker candidates are often
related to markers of inflammatory activity that are already in clinical use (most commonly to
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)), whereas their indepen-
dent marker potential may remain limited [3,5,7]. Our recent approach is to study the activa-
tion of intracellular signaling pathways in leukocytes, using phosphospecific whole blood flow
cytometry, as sign of leukocyte activation in inflammatory disease conditions [8–13]. The
method is considered applicable for immune status determination before starting immune-
modulating therapy in inflammatory diseases [14].
STATs (signal transducers and activators of transcription) are pivotal cytoplasmic tran-
scription factors that become activated by phosphorylation and migrate into the nucleus.
STAT activation usually takes place when extracellular stimuli, e.g. various cytokines and
growth factors, bind to their cell surface receptors and trigger intracellular phosphorylation
cascades [15–17]. STAT3 regulates critical cellular processes such as growth, survival and
transcription of inflammatory genes [16–19]. Activation of STAT3 has been described in
monocytes from synovial fluid [20] and in T cell infiltrate [21] in the joints of patients with
RA, and results from experimental arthritis models support the concept that STAT3 pro-
motes arthritis when activated in the joints [21,22]. We first got evidence that STAT3 phos-
phorylation can be linked to the activity of RA and the disease process when we screened,
along with signaling profiles of patients with a history of reactive arthritis [11], patients with
early RA. In these preliminary experiments, blood lymphocytes and monocytes from the
patients with RA revealed constitutive STAT3 phosphorylation [23]. This prompted us to
study constitutive STAT3 phosphorylation in subtypes of blood leukocytes of patients with
recent-onset, untreated RA in relation to disease activity and treatment response in the pres-
ent study.
The results show that constitutive STAT3 phosphorylation in blood leukocytes of patients
with early DMARD-naïve RA associates with disease activity, plasma levels of proinflamma-
tory cytokines IL-6, IL-17 and IL-21, and treatment response. The findings introduce STAT3
phosphorylation in circulating leukocytes, especially in CD4+ T lymphocytes, as a potential
novel biomarker to predict treatment response in early RA.
Materials and Methods
Subjects
The study includes 25 patients diagnosed with RA at the Division of Rheumatology, Helsinki
University Central Hospital, from April 2010 to October 2011. The patients fulfilled the Ameri-
can College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010
classification criteria [24]. At baseline, the patients had received no DMARDs or oral
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corticosteroids. They did not take non-steroidal anti-inflammatory drugs regularly either
before or after entering the study.
Laboratory and hospital personnel who did not have autoimmune diseases or immunosup-
pressive medication served as healthy reference subjects (n = 17).
The study protocol was approved by the Ethical Review Board of the Joint Authority for the
Hospital District of Helsinki and Uusimaa, and written informed consent was obtained from
each patient.
Clinical evaluation
A comprehensive clinical and laboratory evaluation was undertaken at entry concomitant to
blood sampling, and after follow-up time (median 12 months, range 6 to 18 months) to assess
outcome. 66/68 joints were evaluated for swelling and pain, patient’s global assessment of dis-
ease activity was recorded on a 100 mm visual analogue scale, and laboratory measurements
including ESR and serum CRP level were logged. Disease activity score using 28 joints
(DAS28) was calculated [25]. Treatment response was evaluated using EULAR response crite-
ria [26]. Postero-anterior radiographs of hands and feet were obtained at baseline and presence
of erosions was evaluated by an experienced rheumatologist (MLR).
Blood samples
A 4-ml blood sample was taken, at baseline and at follow-up, by venipuncture from the antecu-
bital vein into a Falcon polypropylene tube (Becton Dickinson) supplemented with 400 μl of
pyrogen-free acid citrate dextrose solution A (ACD-A, Baxter). Cells for flow cytometry were
prepared within 3 hours of blood sampling. Plasma was separated from the remaining blood
sample by centrifugation and frozen in aliquots at -80°C.
Preparing leukocytes for flow cytometry
Blood samples were prepared according to protocol by Becton Dickinson [27]. All antibodies
were also purchased from BD. The optimal antibody amounts and the compatibility of the
antibodies with the permeabilization procedure were tested in preliminary experiments.
Briefly, three 100-μl aliquots of blood were put into polystyrene tubes (BD). The tubes were
supplemented with of either a) anti-CD4-FITC/CD8-PE antibody (mouse anti-human IgG1, κ,
clone SK3/SK1, 5 μl), b) anti-CD19-FITC (mouse anti-human IgG1, κ, clone SJ25C1, 9 μl), or
c) anti-CD14-FITC (mouse anti-human IgG2b, κ, clone MᵩP9, 5 μl). Following 15-minute
incubation at +37°C, the leukocytes were fixed and erythrocytes lysed by adding 1X Lyse/Fix
buffer. After pelleting, leukocytes were washed with Stain Buffer and permeabilized by Perm
Buffer III at -20°C for 30 min. Cells were pelleted and washed with Stain Buffer, after which all
tubes were supplemented with anti-STAT3 (pSer727)-Alexa Fluor 647 antibody (mouse anti-
human IgG1, clone 49/p-Stat3, 5 μl), and tubes a and b also with anti-CD3-PerCP antibody
(mouse anti-human IgG1, κ, clone SK7, 9 μl), in 100 μl of Stain Buffer. Following incubation at
room temperature protected from light for 20 min, the cells were washed in Stain Buffer and
resuspended in 300 μl of Stain Buffer. The samples were kept on ice for a maximum of 4 hours
until flow cytometric acquisition.
Flow cytometry
Flow cytometric data were acquired on FACSCantoII flow cytometer and analyzed with FACS-
Diva software (BD BioSciences, San Jose, CA), as described previously [9]. CD4+ and CD8+ T
lymphocytes, CD19+ B lymphocytes and CD14+ monocytes were identified and pSTAT3
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fluorescence intensity of the respective histograms was determined as relative fluoresence units
(RFU). The proportion of pSTAT3 positive (pSTAT3+) cells in the patients’ samples was deter-
mined as described previously [9,10]. In brief, a marker was set on each histogram from a
healthy subject’s sample obtained within a week from that of a patient’s sample so that it
encompassed less than but as close as possible to 5% of the events, and the markers were then
copied to the respective histograms from the patient’s sample. If a marker encompassed more
than 5% of the events, the patient was said to be pSTAT3+ for the corresponding leukocyte sub-
set. Each healthy subject studied served as a reference for one to three patients. The use of the
proportion of pSTAT3+ cells, as compared to that of fluorescence intensity values, aids to mini-
mize the variation related to phosphospecific flow cytometry [28] and provides a more sensi-
tive and illustrative way to reveal constitutive phosphorylation occurring within leukocyte
populations of the patients.
Plasma IL-6, IL-17 and IL-21 determination
Plasma levels of IL-6, IL-17 and IL-21 were determined by enzyme-linked immunoassay
(ELISA) by using the reagents from eBioscience Inc (San Diego, CA, USA). The detection lim-
its and inter-assay coefficients of variation were 0.39 pg/ml and 1.9% for IL-6, 0.98 pg/ml and
6.3% for IL-17, and 15.6 pg/ml and 5.7% for IL-21. In the immunoassays, possible influence of
rheumatoid factor and related compounds present in the patient samples was tested by adding
commercially available heterophilic blocking agent HeteroBlock (Omega Biologicals, Bozeman,
MT, USA) in the samples in increasing concentrations up to 600 μg/ml as recommended by
Todd et al. [29]. No influence on IL-6 concentrations was found while when measuring IL-17
and IL-21 concentrations, the samples were treated with 300 μg/ml and 150 μg/ml of Hetero-
Block blocking reagent, respectively.
Statistical analysis
The data are presented as means with standard deviations (SD), medians with interquartile
range (IQR), or counts with percentages. Statistical comparisons were made by using bootstrap
type t-test, permutation test, Mann-Whitney U test with exact p values and permutation type
analysis of co-variance. However, as sample size was small and some variables were skewed,
exact and resampling-based (Monte Carlo permutation and bootstrap) methods were used to
achieve significance level and 95% confidence intervals (CI). Correlations were estimated by
Spearman’s correlation coefficient method. Exact logistic regression models [30] were used to
investigate factors related to treatment response. Receiver operating characteristic (ROC)
curves were constructed to determine the predictive ability of baseline markers that corre-
sponds to the EULAR response, with bias corrected bootstrap CI. Stata 13.1 (StataCorp LP,
College Station, TX, USA) statistical package was used for the analyses.
Results
Clinical course and treatment
A total of 25 recently diagnosed DMARD naïve RA patients participated in the study (Table 1).
After blood sampling 24 patients started DMARD (methotrexate, sulfasalazine, hydroxychlor-
oquine) therapy according to the national guidelines [31] and EULAR recommendations [32]:
10 patients (40%) one DMARD, 6 patients (24%) a combination of 2 DMARDs, 7 patients
(28%) a combination of 3 DMARDs, and 1 patient (4%) received a biological DMARD (tocili-
zumab) and methotrexate. In addition, 10 patients (40%) started a course of low-dose ( 10
mg/day) oral prednison. During follow-up the drug treatment was modified, targeting to
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remission, in line with the national and EULAR recommendations [31,32]. At follow-up, 22 of
25 patients (88%) were on DMARDs and 4 patients (16%) received oral prednison. The
EULAR treatment response was good in 17 patients (68%), moderate in 2 patients (8%), and 6
patients (24%) did not respond (Table 1).
Table 1. Baseline characteristics according to EULAR response at follow-up.
Baseline variables EULAR response at follow-up p value
No or moderate, N = 8 Good, N = 17
Demographics
Number of women, % 8 (100) 10 (59) 0.057
Age, years, mean (SD) 45 (15) 51 (15) 0.38
Duration of symptoms, months, mean (SD) 15 (13) 18 (21) 0.74
RF positive, n (%) 7 (88) 13 (76) 0.99
ACPA positive, n (%) 7 (88) 14 (82) 0.99
Measures of disease activity
DAS28, mean (SD) 2.98 (1.61) 4.31 (1.37) 0.042
Erythrocyte sedimentation rate, mm/h, mean (SD) 14 (14) 30 (24) 0.097
Serum C-reactive protein, mg/l, mean (SD) 3 (1) 24 (28) 0.012
Number of swollen joints, 0–66, mean (SD) 8 (5) 9 (6) 0.69
Number of tender joints, 0–68, mean (SD) 6 (4) 9 (5) 0.19
Patient’s global assessment, 0-100mm VAS, mean (SD) 44 (31) 44 (17) 0.98
Radiography
Patients with erosions, hands or feet, n (%) 1 (12) 5 (29) 0.62
Plasma cytokine levels*
IL-6, pg/ml, median (min-max) 4.6 (1.8–126.4) 9.3 (1.8–85.7) 0.16
IL-17, pg/ml, median (min-max) 4.3 (2.7–9.8) 7.2 (1.0–21.6) 0.12
IL-21, pg/ml, median (min-max) 264 (121–598) 279 (39–763) 0.72
pSTAT3†
CD4+ T cells
RFU, mean (SD) 596 (106) 752 (149) 0.011
pSTAT3+, n (%) 1 (12) 13 (76) 0.007
CD8+ T cells
RFU, mean (SD) 546 (95) 627 (103) 0.038
pSTAT3+, n (%) 2 (25) 11 (65) 0.097
CD19+ B cells
RFU, mean (SD) 442 (88) 432 (115) 0.83
pSTAT3+, n (%) 2 (25) 5 (29) 0.99
CD14+ monocytes
RFU, mean (SD) 838 (179) 933 (289) 0.41
pSTAT3+, n (%) 4 (50) 8 (47) 0.99
Abbreviations: ACPA = anti-citrullinated protein antibody, DAS28 = 28 joint Disease Activity Score, RF = rheumatoid factor, RFU = relative ﬂuorescence
unit, VAS = visual analogue scale.
*Median (min-max) values for healthy reference subjects (n = 17); IL-6: 1.2 (0.8–2.9) pg/ml, IL-21: 151 (39–467) pg/ml, IL-17: 4.5 (1.0–19.2) pg/ml.
†Mean (SD) values for healthy reference subjects (n = 17); CD4+ T cells: 638 (122) RFU, CD8+ T cells: 596 (114) RFU, CD19+ B cells: 463 (89) RFU,
CD14+ monocytes: 829 (443) RFU.
doi:10.1371/journal.pone.0137385.t001
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pSTAT3 positivity (pSTAT3+) associates with disease activity and
treatment response
At baseline, constitutive STAT3 phosphorylation was commonly found in circulating leuko-
cytes from patients with recent-onset RA: CD4+ T cells from 14 patients (56%), CD8+ T cells
from 13 patients (52%), CD19+ B cells from 7 patients (28%), and CD14+ monocytes from 12
patients (48%) were pSTAT3+. Interestingly, DAS28 score was associated with pSTAT3+ CD4+
T cells (Fig 1), suggesting an association between constitutive STAT3 phosphorylation in CD4+
T lymphocytes and disease activity in early RA.
Six of the 25 patients had erosive disease at baseline. Interestingly, all those six expressed
pSTAT3+ CD8+ T cells whereas there were no erosions in patients with pSTAT3- CD8+ T cells
(p = 0.02). This finding suggests that early erosive RA is associated with activation of cytotoxic
T lymphocytes.
During the follow-up time, DAS28 score decreased significantly more in patients in whom
CD4+ or CD8+ T cells were pSTAT3+ at baseline than in those in whom they were not: the
mean ratio of the change in DAS28 (follow-up adjusted for baseline DAS28) was 3.24-fold
(95% CI 1.28 to 16.14) higher in patients with pSTAT3+ CD4+ T cells than in patients with
pSTAT3- CD4+ T cells, and 1.61-fold (95% CI 1.09 to 2.56) higher in patients with pSTAT3+
CD8+ T cells than in patients with pSTAT3- CD8+ T cells.
To further determine the actual improvement during follow-up, EULAR response criteria
were used. Patients with good response were categorized as good responders and patients with
moderate or no response as non-responders. Thirteen out of the 14 patients with pSTAT3+
CD4+ T cells at baseline reached a good EULAR treatment response and one patient was a
Fig 1. DAS28 scores (mean with 95% CI) at baseline according to baseline pSTAT3 positivity
(pSTAT3+) of CD4+ and CD8+, CD19+, and CD14+ leukocytes. Closed symbols denote pSTAT3+ patients
and open symbols pSTAT3- patients. p values denote significance between pSTAT3+ and pSTAT3-.
doi:10.1371/journal.pone.0137385.g001
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non-responder (Table 1, Fig 2) indicating that presence of pSTAT3+ CD4+ T cells in early RA
may serve as predictor of good treatment response. Of the 11 patients not having pSTAT3+
CD4+ T cells at baseline, seven were non-responders to therapy and four had a good response
(Fig 2, baseline data).
Fig 2. The pSTAT3 fluorescence intensity of lymphocyte subsets andmonocytes at baseline and at
follow-up according to EULAR treatment response. Yes denotes good response, No denotes no or
moderate response, and p values indicate significance between the two groups. Closed symbols denote
pSTAT3+ patients and open symbols pSTAT3- patients.
doi:10.1371/journal.pone.0137385.g002
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pSTAT3 fluorescence intensity associates with disease activity,
systemic inflammation and treatment response
As presented in the previous paragraphs, the presence of pSTAT3+ leukocytes was associated
with disease activity and treatment response in early RA. Therefore we aimed to investigate if
the intensity of pSTAT3 fluorescence (depicting the magnitude of STAT3 phosphorylation) is
also a determinant of disease activity and treatment response in our patients proving evidence
of quantitative association and potential causality.
pSTAT3 fluorescence intensity in CD4+ T lymphocytes correlated positively with DAS28
score at baseline (Table 2). Furthermore, pSTAT3 fluorescence intensity of each leukocyte sub-
type showed a positive correlation with erosion score, CD8+ T cells showing the strongest cor-
relation (Table 2).
Circulating levels of CRP and proinflammatory cytokines, such as IL-6, are considered to
serve as markers of systemic inflammation. At baseline, pSTAT3 fluorescence intensity of
CD4+ T cells and monocytes correlated positively with IL-6 level, that of B cells correlated with
IL-17 level, and that of each leukocyte subtype with IL-21 level (Table 2).
pSTAT3 fluorescence intensities in CD4+ and CD8+ T lymphocytes at baseline were associ-
ated with good treatment response (Table 1), as was serum CRP level. Multivariate exact logis-
tic regression analysis was used to test for the independent explanatory value of pSTAT3
fluorescence intensity for treatment response. After adjusting for CRP level, pSTAT3 fluores-
cence intensity in CD4+ T cells statistically significantly predicted treatment response but that
in CD8+ T cells did not.
During the follow-up time, pSTAT3 fluorescence intensity generally decreased (Fig 2). The
decrease was significant among good responders in CD4+ T cells (p = 0.01) and CD14+ mono-
cytes (p = 0.02). Also, there was a significant decrease in ESR (p<0.001), CRP (p<0.001), IL-6
(p<0.001), IL-17 (p<0.001) and IL-21 levels (p = 0.04) among good responders and in IL-17
Table 2. Correlations between baseline characteristics and pSTAT3 fluorescence intensity of lymphocyte subsets andmonocytes at baseline.
CD4+ CD8+ CD19+ CD14+
r (95% CI) r (95% CI) r (95% CI) r (95% CI)
Age 0.26 (-0.17 to 0.65) 0.20 (-0.22 to 0.62) -0.01 (-0.47 to 0.45) -0.01 (-0.42 to 0.42)
Duration of symptoms -0.28 (-0.60 to 0.10) -0.03 (-0.41 to 0.36) 0.33 (-0.03 to 0.70) 0.06 (-0.31 to 0.43)
RF 0.21 (-0.11 to 0.52) 0.03 (-0.30 to 0.37) 0.10 (-0.27 to 0.48) 0.37 (-0.02 to 0.67)
DAS28 0.42* (0.10 to 0.77) 0.21 (-0.21 to 0.65) -0.02 (-0.45 to 0.42) 0.26 (-0.18 to 0.69)
Erythrocyte sedimentation rate 0.30 (-0.06 to 0.66) 0.08 (-0.30 to 0.47) -0.26 (-0.70 to 0.18) 0.10 (-0.34 to 0.53)
Serum C-reactive protein 0.29 (-0.08 to 0.66) 0.20 (-0.16 to 0.55) -0.27 (-0.69 to 0.16) 0.09 (-0.33 to 0.51)
Number of swollen joints, 0–66 0.23 (-0.18 to 0.63) 0.05 (-0.39 to 0.49) 0.19 (-.26 to 0.63) 0.28 (-0.20 to 0.75)
Number of tender joints, 0–68 0.25 (-0.14 to 0.63) 0.18 (-0.25 to 0.61) 0.26 (-0.13 to 0.65) 0.33 (-0.10 to 0.76)
Patient’s global assessment, 0-100mm VAS -0.01 (-0.44 to 0.42) -0.18 (-0.62 to 0.25) -0.05 (-0.45 to 0.35) -0.12 (-0.51 to 0.26)
Erosion score† 0.44* (0.14 to 0.73) 0.62*** (0.40 to 0.85) 0.55** (0.28 to 0.82) 0.42* (0.13 to 0.71)
Plasma IL-6 0.45* (0.07 to 0.84) 0.07 (-0.38 to 0.52) 0.13 (-0.28 to 0.53) 0.41* (0.08 to 0.73)
Plasma IL-17 0.33 (-0.04 to 0.71) 0.26 (-0.19 to 0.71) 0.42* (0.04 to 0.80) 0.40 (-0.01 to 0.80)
Plasma IL-21 0.40* (0.06 to 0.74) 0.48* (0.17 to 0.80) 0.64*** (0.32 to 0.96) 0.68*** (0.48 to 0.89)
Abbreviations: CI = conﬁdence interval, r = Spearman correlation coefﬁcient, for other abbreviations see Table 1.
†Number of eroded joints in radiographs of hands and feet.
*p<0.05
**p<0.01
***p<0.001.
doi:10.1371/journal.pone.0137385.t002
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levels among non-responders (p = 0.01). At follow-up, the pSTAT3 fluorescence intensities in
CD4+ T cells and CD14+ monocytes and as well as the levels of ESR, CRP, IL-6, IL-17 and IL-
21 of good responders were close to those of non-responders (Table 3).
The ability of cytokines, pSTAT3 fluorescence intensity, and C-reactive
protein to predict EULAR treatment response
To evaluate the ability of pSTAT3 fluorescence intensity to predict the EULAR response, ROC
curves were generated (Fig 3). The AUC values of pSTAT3 fluorescence intensities of CD4+ and
CD8+ T cells were close to the AUC of CRP and slightly higher than those of IL-6 and IL-17.
Discussion
The results show that STAT3 is frequently phosphorylated in circulating leukocyte subsets of
patients with recent-onset untreated RA. Our findings confirm the results of previous reports
[23,33] and extend them by showing that constitutive STAT3 phosphorylation of CD4+ T cells
identifies a subgroup of RA patients characterized by high disease activity, as determined by
DAS28, presence of systemic inflammation, as determined by plasma CRP level, and good
EULAR response to treatment with DMARDs. Constitutive phosphorylation of STAT3 in
CD4+ T cells was recently found to occur in patients with undifferentiated arthritis in whom it
served as a biomarker of progression to RA [34]. If this finding and ours are confirmed by
other research groups, constitutive STAT3 phosphorylation may aid in developing treatment
strategies for individual patients with undifferentiated arthritis and recent-onset untreated RA.
At present, constitutive STAT3 phosphorylation of the RA patients’ CD4+ T cells is consid-
ered to be driven by IL-6 [33,34]. In accordance with this, our results showed a positive correla-
tion between plasma IL-6 levels and pSTAT3 fluorescence intensity in CD4+ T cells and
monocytes at baseline. IL-6, a multifunctional cytokine, is associated with several molecular
and cellular characteristics of inflammation in RA [35]. Recent studies have further brought up
the roles of IL-6 in systemic inflammation in RA, e.g. cytokine and chemokine production of
peripheral blood mononuclear cells (PBMC) [36], and the potential of plasma IL-6 levels to
serve as a biomarker of structural damage in the joints during the first years of RA (indepen-
dently of CRP levels) [37]. Also, as IL-6/STAT3 signaling has been shown to promote the dif-
ferentiation of naïve T cells into B cell helper T cells [38], the activation of STAT3 by IL-6 in
CD4+ T cells may expand cellular activation to B cells to enhance the development of RA [37].
A novel finding in the present study was that plasma levels of IL-21 were positively correlated
with pSTAT3 fluorescence intensity in all leukocyte subtypes studied. IL-21 modulates, for
example, immune responses of both T cells and B cells [38,39]. Our results also showed that
plasma level of IL-17 correlates with pSTAT3 fluorescence intensity in B cells. IL-17 is the
major contributor in developing the Th17 type of immune response and considered to play
Table 3. Erythrocyte sedimentation rate and levels of C-reactive protein and cytokines at follow-up according to EULAR response.
Variables EULAR response at follow-up p value
No or moderate, N = 8 Good, N = 17
Erythrocyte sedimentation rate, mm/h, mean (SD) 14 (3) 6 (5) 0.042
Serum C-reactive protein, μg/ml, mean (SD) 5 (6) 2 (1) 0.28
IL-6, pg/ml, median (min-max) 4.2 (1.7–136.6) 3.6 (1.9–13.6) 0.83
IL-17, pg/ml, median (min-max) 2.0 (1.9–2.3) 2.3 (1.9–6.7) 0.043
IL-21, pg/ml, median (min-max) 268 (54–816) 145 (31–579) 0.24
doi:10.1371/journal.pone.0137385.t003
STAT3 Phosphorylation in Recent-Onset Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0137385 September 9, 2015 9 / 15
Fig 3. Predictive ability of pSTAT3 fluorescence intensity of leukocyte subsets, C-reactive protein and
cytokines for EULAR treatment response. Area under the curve (AUC) values were determined for the
baseline markers presented in Table 1. The dashed lines denote no information line.
doi:10.1371/journal.pone.0137385.g003
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numerous roles in the pathogenesis of RA [40]. Like IL21, IL17 is a direct target of pSTAT3
[15]. Clearly, the molecular relationships between constitutive STAT3 phosphorylation in cir-
culating leukocyte subsets and plasma cytokine levels described in the present study, and sys-
temic inflammation remain to be elucidated. In addition to altered cytokine milieu in
peripheral blood, constitutive STAT3 phosphorylation in RA may involve aberrations in the
expression or activation of intracellular kinases or negative regulators upstream of STAT3 or in
transcriptional activity of STAT3. In this context it is of note that elevated levels of STAT3
mRNA in circulating monocytes and CD3+ T cells [33] and downregulation of suppressor of
cytokine signaling 3 (a negative STAT3 pathway regulator) in CD4+ T cells [41] have been
reported in RA patients.
We observed radiological erosions in six of 25 patients with recent-onset untreated RA at
the time of diagnosis. A novel finding was that the number of eroded joints correlated with
pSTAT3 fluorescence intensity in all leukocyte subtypes studied, and the correlation was stron-
gest for CD8+ T cells. This may reflect the influence of IL-21, as IL-21 has been reported to be
up-regulated in the synovium and synovial fluid of patients with RA and to enhance osteoclas-
togenesis in vitro [42]. In this context it is of note that serum levels of granzyme B, an acidic
protease expressed by cytotoxic T lymphocytes, have been reported to be increased in arthritis
and positively correlated with erosive RA [4], and that IL-21 increases its expression in CD8+ T
cells [43]. Also, additional cytokines may be able to activate both STAT3 activation and gran-
zyme B expression in CD8+ T cells [44]. Altogether, regardless of the mediating mechanism,
granzyme B could be one of the factors connecting pSTAT3+ CD8+ T cells and presence of
erosions.
Another novel finding in the present study was that pSTAT3 positivity in CD4+ T cells in
recent-onset untreated RA is in relationship with successful response to therapy with
DMARDs, as evaluated by EULAR response and effectual decrease in DAS28 after one year of
treatment. Furthermore, during the follow-up time, STAT3 phosphorylation level in CD4+ T
cells and monocytes decreased significantly among good responders, whereas there was no sta-
tistical difference between baseline and follow-up STAT3 phosphorylation levels among non-
responders. Accordingly, Anderson et al. [34] have also reported that DMARD treatment
depressed constitutive STAT3 phosphorylation. Even though the rationale of the result war-
rants further studies, an explanation may be provided by the molecular effects of DMARDs
that directly counteract STAT3 activation-related phenomena. In this context it is noteworthy
that activated STAT3 can activate over 3000 genes in CD4+ T cells [18], including genes
involved in cell adhesion and migration to the joints [45,46], as well as genes important for pro-
liferation and cell cycle regulation [17,18,47,48] analogously to malignant cells in which
STAT3 is constitutively activated to promote prolonged functioning of dysregulated cells
[15,16,47–50]. Considering DMARDs, sulfasalazine, for example, interferes with CD11b/
CD18-mediated leukocyte recruitment [51] and chloroquine suppresses cell-cell adhesion
mediated by β1 integrins [52]. Furthermore, considering that the levels of systemic inflamma-
tion biomarkers significantly decreased among good responders in our study, it is notable that
methotrexate alone or in combination with sulfasalazine reduces circulating levels of IL-6 [53],
and hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production from PBMC [54]. Alto-
gether, an interesting possibility introduced in the current study is that pSTAT3 positivity in
peripheral blood CD4+ T cells could be a marker indicating a disease form of RA that is effec-
tively alleviated by synthetic DMARDs.
Although constitutive STAT3 phosphorylation in CD4+ T cells of RA patients with recent-
onset disease was clear in the present study and the previous studies [23,33,34], it was not evi-
dent in a recent study of RA patients refractory to DMARD therapy [55]. In the study by Iso-
mäki et al. [33], 11/15 patients had long-standing RA. Because DMARD therapy depresses
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STAT3 phosphorylation, as shown previously [34] and in the present study, differences in
DMARDs taken by the patients and disease duration may explain the discrepancy. Another
explanation for discrepancy involves the methods used. To minimize ex vivo leukocyte activa-
tion, we and the two other groups [33,34] studied whole blood samples whereas Ortiz et al.
[55] separated mononuclear cells from blood by density gradient centrifugation. Sample han-
dling ex vivo readily promotes leukocyte activation [56–58], which may distort constitutive
STAT phosphorylation data. Meticulous sample handling is a prerequisite for the study of con-
stitutive STAT3 phosphorylation.
The present results show that constitutive STAT3 phosphorylation is common in circulating
leukocytes of patients with recent-onset untreated RA, associates with active disease when pres-
ent in CD4+ T cells, associates with presence of erosions when present in CD8+ T cells, and
identifies a patient group designated by the presence of systemic inflammation and good
response to treatment with synthetic DMARDs when present in CD4+ T cells. Optimally, the
whole blood flow cytometric method we used may provide a rapid and easy way to recognize
the RA patients in whom aberrant STAT3 signaling takes place. In the future, STAT3 phos-
phorylation status of leukocytes may, either alone or as part of a larger signaling profile, be
determined for designing most beneficial and precisely targeted personalized treatment for
patients with recent-onset RA.
Conclusions
Constitutive STAT3 phosphorylation in circulating leukocytes is common in recent-onset
untreated rheumatoid arthritis and identifies patients characterized by the presence of systemic
inflammation and good EULAR response to DMARD treatment.
Measurement of intracellular STAT3 phosphorylation in circulating T lymphocytes may
provide a novel predictive biomarker in RA and warrants further studies.
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